
亚太地区左心室辅助装置市场预测至 2028 年 – COVID-19 影响和区域分析 – 血流类型(脉动血流和非脉动血流)、设计(植入式心室辅助装置和经皮心室辅助装置)以及申请(移植桥梁、目的地治疗、康复桥梁和候选桥梁)
No. of Pages: 111 | Report Code: BMIRE00027901 | Category: Life Sciences
No. of Pages: 111 | Report Code: BMIRE00027901 | Category: Life Sciences
印度和中国等新兴国家预计将为左心室辅助装置市场参与者提供显着的增长机会,这主要是由于增长患者人数、研发活动增加、CVD意识增强、可支配收入激增、医疗基础设施改善以及与发达国家相比相对宽松的政策。在过去十年中,这些新兴市场的心力衰竭病例也持续增加。为了利用新兴市场普遍存在的高增长机会,制造商正在采取研发等战略活动来扩展这些国家的业务。根据世界银行的数据,2018年至2019年,中国和印度的医疗保健支出分别增长了5.35%和3.01%。根据印度品牌资产基金会的数据,印度医疗保健行业的年复合增长率高达17%; 2020 年价值 2800 亿美元,其中医院约占收入的 71%。在中国,2011 年至 2017 年,私立医院数量翻了一番,达到 16,900 家。私立医院约占全国医院总数的57.2%。因此,发展中经济体医疗设施的进步以及医院数量的激增可能会推动亚太左心室辅助装置市场新兴经济体采用 LVAD。
亚太地区左心室辅助装置市场细分为中国、日本、印度、韩国、澳大利亚、韩国和亚太其他地区。该地区的市场增长归因于老年人口的增加、心力衰竭病例的增加、心血管疾病患病率的飙升以及将 LVAD 相关费用纳入保险范围。中国社会经济的快速进步和变化正在影响人们的生活方式,进而增加心血管疾病的风险。根据 BioMed Central (BMC) 发表的一篇文章,心血管疾病导致中国 40% 以上的死亡。此外,2019年中国心血管疾病患者约12033万人。 CVD进一步导致心力衰竭;因此,心血管疾病病例的增加刺激了中国对 LVAD 的需求。
亚太地区左心室辅助装置市场按流量类型、设计、应用和国家/地区进行细分。
根据流量类型,亚太地区左心室辅助装置市场辅助装置市场分为非脉动流和脉动流。 非脉动细分市场在 2022 年占据最大的市场份额。
根据设计,亚太地区左心室辅助装置市场分为两部分分为植入式心室辅助装置和经皮心室辅助装置。 植入式心室辅助装置细分市场在 2022 年占据最大市场份额。
根据应用情况,亚太地区左心室辅助装置市场为分为目的地治疗、移植桥梁、候选桥梁和康复桥梁。 目标治疗细分市场在 2022 年占据最大市场份额
亚太地区左心室辅助装置市场按国家/地区划分为中国、日本、印度、澳大利亚、韩国和亚太其他地区。 2022 年,中国将主导市场。
ABIOMED Inc;雅培实验室;美敦力公司;利瓦诺瓦有限公司;泰尔茂公司; BiVACOR公司;伊娃心公司;和 BioVentrix Inc 是亚太地区左心室辅助装置市场的领先公司。
Strategic insights for Asia Pacific Left Ventricular Assist Device involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 263.01 Million |
Market Size by 2028 | US$ 370.99 Million |
Global CAGR (2022 - 2028) | 5.9% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 流动类型
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Left Ventricular Assist Device refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Left Ventricular Assist Device Market is valued at US$ 263.01 Million in 2022, it is projected to reach US$ 370.99 Million by 2028.
As per our report Asia Pacific Left Ventricular Assist Device Market, the market size is valued at US$ 263.01 Million in 2022, projecting it to reach US$ 370.99 Million by 2028. This translates to a CAGR of approximately 5.9% during the forecast period.
The Asia Pacific Left Ventricular Assist Device Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Left Ventricular Assist Device Market report:
The Asia Pacific Left Ventricular Assist Device Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Left Ventricular Assist Device Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Left Ventricular Assist Device Market value chain can benefit from the information contained in a comprehensive market report.